• Теги
    • избранные теги
    • Компании2999
      • Показать ещё
      Разное775
      • Показать ещё
      Страны / Регионы393
      • Показать ещё
      Международные организации48
      • Показать ещё
      Люди110
      • Показать ещё
      Формат38
      Показатели83
      • Показать ещё
      Издания19
      • Показать ещё
Gilead Sciences
Выбор редакции
22 сентября, 22:14

Gilead's (GILD) Epclusa Receives Label Expansion in Canada

Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.

22 сентября, 22:14

Gilead's (GILD) Epclusa Receives Label Expansion in Canada

  • 0

Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.

Выбор редакции
21 сентября, 22:30

Why Gilead Sciences Is Flying High With Kite

Gilead Sciences has expanded beyond its leading antiviral drug franchises for the treatment of HIV and hepatitis C with the announced acquisition of Kite Pharmaceuticals, giving Gilead a leading edge in cell therapy technology in oncology.

21 сентября, 21:58

4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

Выбор редакции
19 сентября, 16:55

Should Value Investors Consider Gilead Sciences (GILD) Stock?

Gilead Sciences (GILD) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions.

19 сентября, 16:55

Should Value Investors Consider Gilead Sciences (GILD) Stock?

Gilead Sciences (GILD) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions.

Выбор редакции
19 сентября, 14:09

Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade

Juno Therapeutics Inc (NASDAQ:JUNO) is poised to benefit from a rising acquisition trend. Three weeks ago when Gilead Sciences, Inc. (NASDAQ:GILD) announced it would be acquiring smaller rival biopharma name Kite Pharma Inc (NASDAQ:KITE), traders clearly took notice. If Gilead wanted Kite for its CAR-T cancer therapy and Novartis AG (ADR) (NYSE:NVS) recently won the first-ever FDA approval for its CAR-T based oncology drug, there had to be something to it.

19 сентября, 00:59

"Fast Money" final trades: AMD, INTC and more

The “Fast Money” traders share their final trades for the day including Bank of America, Gilead Sciences, Intel and Advanced Micro Devices.

Выбор редакции
15 сентября, 00:39

4 Biotech Stocks That Show Promise on Sustainable Growth

Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.

14 сентября, 15:53

Options Traders Expect Huge Moves in Gilead Sciences (GILD) Stock

Gilead Sciences (GILD) needs Investors to pay close attention to the stock based on moves in the options market lately.

Выбор редакции
14 сентября, 14:28

Is It Premature to Celebrate Gilead Sciences, Inc.’s (GILD) Kite Pharma Momentum? Jefferies Looks Beyond the Recent Bull Rally

Gilead Sciences, Inc. (NASDAQ:GILD) investors have been throwing a party lately ever since the biotech giant brought Kite Pharma as the best party favor of all- an acquisition that yielded a 16% stock upturn during the last month alone. For perspective, the iShares Nasdaq Biotechnology ETF saw a little over half the same growth in this interval.

13 сентября, 23:23

FANG and the $200 Club

If you don't know what's driving the rally and why, it's time to understand exponential technology change.

13 сентября, 18:25

3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.

12 сентября, 13:18

The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger

The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger

11 сентября, 22:36

Top Stock Reports for Gilead, Oracle & Morgan Stanley

Top Stock Reports for Gilead, Oracle & Morgan Stanley

Выбор редакции
11 сентября, 19:16

Cowen Shares Key Insights on Gilead Sciences, Inc. (GILD) Following Management Meetings

Top analyst Phil Nadeau of Cowen is sharing key insights on Gilead Sciences, Inc. (NASDAQ:GILD) after organizing meetings between investors and senior management in Boston last week. Notably, the company’s COO, CFO the SCO were among a number of top management officials in attendance to field investors questions, especially surrounding the pending acquisition of Kite and its CAR-T platform Axi-Cel. Along with management’s enthusiasm on the potential for Axi-Cel to successfully penetrate the hematologic malignancies market of 200,000 patients in the U.S. and Europe by 2022, the company is additionally confident on its ability to expand Kite's platform with other technologies moving forward.

11 сентября, 16:33

5 Top-Ranked Biotech Stocks to Buy Right Now

If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).

29 июня, 15:40

Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod

Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.

27 июня, 17:03

Gilead's (GILD) HCV Drug Application Accepted in the EU

Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.